New matter | Shanghai stop purchasing an eye drop

On September 20, Shanghai Sunshine Procurement Network issued an announcement saying that the procurement qualifications for procurement of norfloxacin drip (specifications: 8ml: 24mg/support) produced by Xinxiang Huaqing Pharmaceutical Co., Ltd. were suspended for 1 year.

According to the "Notice on the Public Procurement Procurement of the Pharmaceutical Hanging Network in 2018" promulgated in 2018, Shanghai has repeatedly imposed a penalty for suspension of procurement on the suspension of procurement. The document stipulates that if there is an error and missed report in the procurement price information, the drug procurement qualification will be suspended for one year after verification.

Norfloxal Drop Eye Drop Eye Drops are a product with a large amount of ophthalmology. It mainly treats bacterial keratitis and acute bacterial conjunctivitis. At present, there are 27 domestic norfloxacin droplets in China. The production units include the Sinica Pharmaceutical (Wuhu) Co., Ltd. and Anhui Shuangke Pharmaceutical Co., Ltd. Norfloxacin Drops of Xinxiang Huaqing Pharmaceuticals have a small market share.

The owners of Xinxiang Huaqing Pharmaceuticals include erythromycin ointment, erythromycin eye ointment, ristomycin eye ointment, sodium sezotamone pine phosphate, etc. Among them, the national market share of erythromycin ointment The market share of galcinicochloride eye ointment and gydishin ointment of the hydrochloride hydrochloride is about 50%. In 2016, the company's production of erythromycin ointment was discovered unqualified by the Guangdong Pharmaceutical Supervision Bureau for testing due to the content measurement.

Writing ｜ Li Ao

Edit ｜ Jiang Yun Jia Ting

Operation | Twenty -thirty

#Norfloxacin Drop Eye Drip ## 采#

- END -